Effective inhibition of nasopharyngeal carcinoma in vitro and in vivo by targeting glycolysis with oxamate

International Journal of Oncology

Volumn 43, Issue 5, 2013, Pages 1710-1718

  Li, Xiaobing ^a   Lu, Wenhua ^a   Hu, Yumin ^a   Wen, Shijun ^a   Qian, Chaonan ^a   Wu, Wenjing ^a   Huang, Peng ^a,b  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cancer metabolism; Glycolysis; Nasopharyngeal carcinoma; Oxamate

Indexed keywords

ADENOSINE TRIPHOSPHATE; LACTATE DEHYDROGENASE; LACTIC ACID; OXAMIC ACID; REACTIVE OXYGEN METABOLITE; ROTENONE;

AEROBIC GLYCOLYSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BODY WEIGHT; CANCER CELL; CELL PROLIFERATION; CELL VIABILITY; COLONY FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; ENERGY METABOLISM; ENZYME ACTIVITY; EPITHELIUM CELL; G2 PHASE CELL CYCLE CHECKPOINT; GLUCOSE TRANSPORT; GLYCOLYSIS; HYPOXIA; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL RESPIRATION; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; TUMOR CELL LINE; TUMOR GROWTH; TUMOR VOLUME;

ADENOSINE TRIPHOSPHATE; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; COLONY-FORMING UNITS ASSAY; FLOW CYTOMETRY; GLUCOSE; GLYCOLYSIS; HUMANS; L-LACTATE DEHYDROGENASE; LACTIC ACID; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MICE, INBRED BALB C; MICE, NUDE; MITOCHONDRIA; NASOPHARYNGEAL NEOPLASMS; OXAMIC ACID; REACTIVE OXYGEN SPECIES;

EID: 84885028952     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2080     Document Type: Article

References (38)

1. Huang TR, Zhang SW, Chen WQ, et al: Trends in nasopharyngeal carcinoma mortality in China, 1973-2005. Asian Pac J Cancer Prev 13: 2495-2502, 2012.
2. Cheng SH, Jian JJ, Tsai SY, et al: Prognostic features and treatment outcome in locoregionally advanced nasopharyngeal carcinoma following concurrent chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 41: 755-762, 1998.
3. Toh HC, Ha TC and Wee J: Personalised medicine in nasopharyngeal cancer. Lancet Oncol 13: 568-569, 2012.
4. Ayyanathan K, Kesaraju S, Dawson-Scully K and Weissbach H: Combination of sulindac and dichloroacetate kills cancer cells via oxidative damage. PLoS One 7: e39949, 2012.
5. Warburg O: On the origin of cancer cells. Science 123: 309-314, 1956.
6. Jadvar H: Imaging evaluation of prostate cancer with (18)F- fluorodeoxyglucose PET/CT: utility and limitations. Eur J Nucl Med Mol Imaging 40 (Suppl 1): 5-10, 2013.
7. Schulze A and Harris AL: How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature 491: 364-373, 2012.
8. Erdem V, Selimoglu Sen H, Komek H, et al: Prognostic factors in non-small cell lung cancer patients and prognostic importance of PET/CT SUV max value. Tuberk Toraks 60: 207-217, 2012 (In Turkish).
9. Chan WK, Kwong DL, Yeung DW, Huang B and Khong PL: Prognostic impact of standardized uptake value of F-18 FDG PET/CT in nasopharyngeal carcinoma. Clin Nucl Med 36: 1007-1011, 2011.
10. Sandulache VC, Ow TJ, Pickering CR, et al: Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells. Cancer 117: 2926-2938, 2011.
11. Zhou GQ, Tang LL, Mao YP, et al: Baseline serum lactate dehydrogenase levels for patients treated with intensity-modulated radiotherapy for nasopharyngeal carcinoma: a predictor of poor prognosis and subsequent liver metastasis. Int J Radiat Oncol Biol Phys 82: e359-365, 2012.
12. Brown JE, Cook RJ, Lipton A and Coleman RE: Serum lactate dehydrogenase is prognostic for survival in patients with bone metastases from breast cancer: a retrospective analysis in bisphosphonate-treated patients. Clin Cancer Res 18: 6348-6355, 2012.
13. Zen HG, Jame JM, Chang AY, et al: Nasopharyngeal carcinoma with bone marrow metastasis. Am J Clin Oncol 14: 66-70, 1991.
14. Fantin VR, St-Pierre J and Leder P: Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 9: 425-434, 2006.
15. Kim SH and Lee GM: Down-regulation of lactate dehydrogenase-A by siRNAs for reduced lactic acid formation of Chinese hamster ovary cells producing thrombopoietin. Appl Microbiol Biotechnol 74: 152-159, 2007.
16. Sheng SL, Liu JJ, Dai YH, Sun XG, Xiong XP and Huang G: Knockdown of lactate dehydrogenase A suppresses tumor growth and metastasis of human hepatocellular carcinoma. FEBS J 279: 3898-3910, 2012.
17. Yao F, Zhao T, Zhong C, Zhu J and Zhao H: LDHA is necessary for the tumorigenicity of esophageal squamous cell carcinoma. Tumour Biol 34: 25-31, 2013.
18. Zhang Y, Zhang X, Wang X, et al: Inhibition of LDH-A by lentivirus-mediated small interfering RNA suppresses intestinal-type gastric cancer tumorigenicity through the downregulation of Oct4. Cancer Lett 321: 45-54, 2012.
19. Xu RH, Pelicano H, Zhou Y, et al: Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res 65: 613-621, 2005.
20. Tang Z, Yuan S, Hu Y, et al: Over-expression of GAPDH in human colorectal carcinoma as a preferred target of 3-bromopyruvate propyl ester. J Bioenerg Biomembr 44: 117-125, 2012.
21. Lu W, Hu Y, Chen G, et al: Novel role of NOX in supporting aerobic glycolysis in cancer cells with mitochondrial dysfunction and as a potential target for cancer therapy. PLoS Biol 10: e1001326, 2012.
22. Zeng ZL, Wu MW, Sun J, et al: Effects of the biological clock gene Bmal1 on tumour growth and anti-cancer drug activity. J Biochem 148: 319-326, 2010.
23. Hu Y, Lu W, Chen G, et al: K-ras(G12V) transformation leads to mitochondrial dysfunction and a metabolic switch from oxidative phosphorylation to glycolysis. Cell Res 22: 399-412, 2012.
24. Chen G, Chen Z, Hu Y and Huang P: Inhibition of mitochondrial respiration and rapid depletion of mitochondrial glutathione by beta-phenethyl isothiocyanate: mechanisms for anti-leukemia activity. Antioxid Redox Signal 15: 2911-2921, 2011.
25. Zhao Y, Liu H, Liu Z, et al: Overcoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolism. Cancer Res 71: 4585-4597, 2011.
26. Hammoudi N, Ahmed KB, Garcia-Prieto C and Huang P: Metabolic alterations in cancer cells and therapeutic implications. Chin J Cancer 30: 508-525, 2011.
27. Chen Z, Lu W, Garcia-Prieto C and Huang P: The Warburg effect and its cancer therapeutic implications. J Bioenerg Biomembr 39: 267-274, 2007.
28. Fanciulli M, Bruno T, Giovannelli A, et al: Energy metabolism of human LoVo colon carcinoma cells: correlation to drug resistance and influence of lonidamine. Clin Cancer Res 6: 1590-1597, 2000.
29. Sun W, Liu Y, Glazer CA, et al: TKTL1 is activated by promoter hypomethylation and contributes to head and neck squamous cell carcinoma carcinogenesis through increased aerobic glycolysis and HIF1alpha stabilization. Clin Cancer Res 16: 857-866, 2010.
30. Seo M, Kim JD, Neau D, Sehgal I and Lee YH: Structure-based development of small molecule PFKFB3 inhibitors: a framework for potential cancer therapeutic agents targeting the Warburg effect. PLoS One 6: e24179, 2011.
31. Elwood JC: Effect of oxamate on glycolysis and respiration in sarcoma 37 ascites cells. Cancer Res 28: 2056-2060, 1968.
32. Liu H, Savaraj N, Priebe W and Lampidis TJ: Hypoxia increases tumor cell sensitivity to glycolytic inhibitors: a strategy for solid tumor therapy (Model C). Biochem Pharmacol 64: 1745-1751, 2002.
33. Zhou M, Zhao Y, Ding Y, et al: Warburg effect in chemosensitivity: targeting lactate dehydrogenase-A re-sensitizes taxol-resistant cancer cells to taxol. Mol Cancer 9: 33, 2010.
34. Zhao YH, Zhou M, Liu H, et al: Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth. Oncogene 28: 3689-3701, 2009.
35. Liu H, Hu YP, Savaraj N, Priebe W and Lampidis TJ: Hypersensitization of tumor cells to glycolytic inhibitors. Biochemistry 40: 5542-5547, 2001.
36. Aghaee F, Pirayesh Islamian J and Baradaran B: Enhanced radiosensitivity and chemosensitivity of breast cancer cells by 2-deoxy-d-glucose in combination therapy. J Breast Cancer 15: 141-147, 2012.
37. Manerba M, Vettraino M, Fiume L, et al: Galloflavin (CAS 568-80-9): a novel inhibitor of lactate dehydrogenase. Chem Med Chem 7: 311-317, 2012.
38. Cheng G, Zielonka J, Dranka BP, et al: Mitochondria-targeted drugs synergize with 2-deoxyglucose to trigger breast cancer cell death. Cancer Res 72: 2634-2644, 2012.